Rapid fat loss from GLP-1 medications like Ozempic can lead to 'Ozempic face', characterized by hollow cheeks and sagging skin. Drinking water, eating a protein-rich diet, and practicing face yoga ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment. Never before was there a drug that actually worked for weight loss.

Ozempic has skyrocketed in popularity as both a diabetes medication and a weight loss aid, but a growing number of patients are reporting an unexpected and puzzling side effect. Some users have ...

Experts have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind. Several studies have linked the shots to conditions that cause inflammation and block blood ...

Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...

Our editors also may be in touch with follow-up questions. Ozempic is a brand-name version of semaglutide, an injectable glucagon-like peptide-1 (GLP-1) receptor agonist medication. One of the ...

Are you a print subscriber? Activate your account. By Ad Age Staff - 2 hours 11 min ago By Ad Age and Creativity Staff - 2 hours 28 min ago By Jack Neff - 3 hours 14 min ago 4 hours 25 min ago 6 ...

He also published one of the first case series that found semaglutide, the active ingredient in Ozempic, to effectively reduce alcohol consumption among six people with addiction. (The drug ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

Jorge Martin joined the Red Bull Rookies Cup for the 2012 season. Unfortunately it was a season plagued by various injuries, but the following year he tried again and finished runner-up behind the ...

Iain Martin is a senior editor who covers tech, startups and venture capital out of London, England. Iain edits the Midas List Europe, Midas Seed and Forbes 30 Under 30 Europe Technology.